A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

By afschroeder • March 31, 2026

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ. A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. Future Oncol. 2026 Mar 30:1-13. doi: 10.1080/14796694.2026.2645982. Epub ahead of print. PMID: 41910021.

Tags: binimetinib, BRAF, Encorafenib, Hematology/Oncology, Non-small cell lung cancer, NSCLC, Publications

Related Posts

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, Saeed A, Beagle B, Kim JY, Wang N, Weeder[...]

Advancing precision health discovery in a genetically diverse health system

Haas R, Margolis MP, Wei A, Yamaguchi TN, Feng J, Tran T, Tozzo V, Queen KJ, Mootor MFE, Patil V, Broudy ME, Tung P, Alam[...]

Alterations in Brain White Matter Tractography in Older Long-Term Breast Cancer Survivors Treated with Chemotherapy

Daniel E, Young JR, Deng F, Patel SK, Sedrak MS, Kim H, Razavi M, Sun CL, Root JC, Ahles TA, Dale W, Chen BT. Alterations[...]